Search Result

Results for "

DOTA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (6) Amino Acid Derivatives (1) Bacterial (1) Biochemical Assay Reagents (40) Carbonic Anhydrase (1) CXCR (3) DNA-PK (2) Drug Derivative (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (2) EGFR (2) FAP (4) Integrin (2) Ligands for Target Protein for PROTAC (1) PARP (1) Peptide-Drug Conjugates (PDCs) (1) Prolyl Endopeptidase (PREP) (1) PROTAC Linkers (5) PSMA (6) Radionuclide-Drug Conjugates (RDCs) (46) Somatostatin Receptor (5)
By Research Areas:	Cancer (69) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Neurological Disease (1)
Click Chemistry:	DBCO (1) PROTAC Synthesis (3) Azide (4) Alkynes (2)

104

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W053583

Tetraxetan DOTA	Biochemical Assay Reagents	Others Cancer
Tetraxetan (DOTA) is a complexing agent, and its complexes have medical applications as contrast agents and in cancer research .

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-131326

DOTA-tris(tBu)ester NHS ester	Biochemical Assay Reagents	Cancer
DOTA-tris(tBu)ester NHS ester is a derivative of DOTA for the labeling of peptides and antibodies .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W038001

DOTA-benzene	Others	Cancer
DOTA-benzene is a DOTA-based small molecule hapten. DOTA-biotin has been used extensively as a hapten for PRIT .

HY-163040

**DOTA-Tyr-Lys-DOTA**	Biochemical Assay Reagents	Inflammation/Immunology
DOTA-Tyr-Lys-DOTA is a DOTA-based small molecule hapten. DOTA-Tyr-Lys-DOTAexhibits rapid clearance and low whole-body retention. DOTA-Tyr-Lys-DOTA can used in study pretargeted radioimmunotherapy .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P5126

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W802013

DOTA-4AMP	Biochemical Assay Reagents	Others
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-163039

DOTA-biotin	Biochemical Assay Reagents	Inflammation/Immunology
DOTA-biotin is a DOTA-based small molecule hapten. DOTA-biotin has low tissue and whole-body retention in mice 4 h postinjection .

HY-W088413

DOTA-amide	Biochemical Assay Reagents	Others
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents	Others
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linker	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Biochemical Assay Reagents	Others
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-157977

DOTA-GA-maleimide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Others
DOTA-GA-maleimide is a macrocyclic chelator, which forms stable complex with metals. DOTA-GA-maleimide is utilized as radiolabelled imaging agent .

HY-12690

DOTA derivative	Drug Derivative	Cancer
DOTA derivative is a cyclic tosamide benzylic derivative.

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as ⁶⁸Ga and ¹⁷⁷Lu) through DOTA to produce radioactive probes ([ ⁶⁸Ga]Ga/DOTA-NI-FAPI-04 and [ ¹⁷⁷Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-W241345

DOTA-bis(tert-butyl)ester	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-bis(tert-butyl)ester is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide conjugates (RDCs). DOTA-bis(tert-butyl)ester can be conjugated with different salts to form different metal chelators, such as (HY-B1244) hydrochloride to obtain DOTA-MN2. DOTA-MN2 can be reacted with [67]Ga-citrate to obtain radiolabeling. When (67)Ga-DOTA-MN2 is incubated in phosphate buffer solution or mouse plasma for 24 hours, it does not undergo significant decomposition. In the biodistribution experiment of NFSa tumor mice, it has high tumor uptake and rapid plasma clearance, and is a good material for SPECT and PET studies.

HY-D2363

DOTA.SA.FAPi TFA	FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-W034551

DOTA-tri(t-butyl ester)	Radionuclide-Drug Conjugates (RDCs)	Others Cancer
DOTA-tri(t-butyl ester) belongs to the DOTA class of chelating agents. DOTA-tri(t-butyl ester) is a key raw material for synthesizing nanospherical magnetic resonance imaging (MRI) contrast agents, which are used in MR angiography and tumor angiogenesis imaging .

HY-139564

DOTA Zoledronate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents	Cancer
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W614269

DOTA-GA(tBu)4	Radionuclide-Drug Conjugates (RDCs)	Others
DOTA-GA(tBu)4 is a macrocyclic chelator used in medical imaging .

HY-164379

DOTA-PEG4-alkyne	Others	Cancer
DOTA-PEG4-alkyne is a linker, and can be used for the labeling of radionuclide .

HY-P10730

DOTA-Lanreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-P10731

DOTA-NAPamide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-140008

DOTA-PEG5-amine	PROTAC Linkers	Cancer
DOTA-PEG5-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-P10732

DOTA-cyclo(RGDfK)	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-159526

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

HY-140752

DOTA-PEG5-azide	PROTAC Linkers	Cancer
DOTA-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-P10729

DOTA-Bombesin (1-14)	Biochemical Assay Reagents	Cancer
DOTA-Bombesin (1-14) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-140314

DOTA-PEG5-C6-DBCO	PROTAC Linkers	Cancer
DOTA-PEG5-C6-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-C6-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-164654

DOTA-PEG10-azide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-140753

DOTA-(t-butyl)3-PEG5-azide	PROTAC Linkers	Cancer
DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-(t-butyl)3-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-164656

DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE	Drug-Linker Conjugates for ADC	Cancer
DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-158072

DOTAM-NHS-ester	Biochemical Assay Reagents	Others
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.

HY-W717743

DOTAM-mono-acid	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W087187

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.

HY-164574

BCN-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.

Cat. No.	Product Name	Type

HY-W053583

Tetraxetan DOTA	Biochemical Assay Reagents
Tetraxetan (DOTA) is a complexing agent, and its complexes have medical applications as contrast agents and in cancer research .

HY-W088413

DOTA-amide	Chelators
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Chelators
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-100133A

DOTA-ADIBO TFA	Chelators
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-W717743

DOTAM-mono-acid	Chelators
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Chelators
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W802013

DOTA-4AMP	Chelators
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Chelators
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-W088413A

DOTA-amide dihydrate	Chelators
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-158072

DOTAM-NHS-ester	Chelators
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Chelators
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-W451440

*Butyne-DOTA-tris(t-butyl ester)*	Chelators
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W539916

Azido-mono-amide-DOTA	Chelators
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W460274

*4-Aminobutyl-DOTA-tris(t-butyl ester)*	Chelators
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-156038

(S)-p-SCN-Bn-DOTA	Chelators
(S)-p-SCN-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-159181

*p-NCS-Bz-DOTA-GA*	Chelators
p-NCS-Bz-DOTA-GA is a bifunctional chelator.

HY-W250929

*Maleimido-mono-amide-DOTA-tris(t-Bu ester)*	Chelators
Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782075

p-NO2-Bn-DOTA	Chelators
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Chelators
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717760

*p-NH2-Bn-DOTA-tetra(t-Bu ester)*	Chelators
p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W749603

*Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)*	Chelators
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-158065

*Azido-mono-amide-DOTA-tris(t-Bu ester)*	Chelators
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Chelators
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-W726767

DO2A	Chelators
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Chelators
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-W053583R

Tetraxetan (Standard)	Biochemical Assay Reagents
Tetraxetan (Standard) is the analytical standard of Tetraxetan. This product is intended for research and analytical applications. Tetraxetan (DOTA) is a complexing agent, and its complexes have medical applications as contrast agents and in cancer research .

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Chelators
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W782081

p-SCN-Bn-oxo-DO3A	Chelators
p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

HY-W782080

p-NH2-Bn-oxo-DO3A	Chelators
p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Target	Research Area

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P5126

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-D2363

DOTA.SA.FAPi TFA	FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-159526

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P6351

*c(avb6)-DOTA* TFA**	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10883

Lutetate tezuvotide tetraxetan	Biochemical Assay Reagents	Cancer
Lutetate tezuvotide tetraxetan is tetrahydrogenated Tetraxetan. Tetraxetan (DOTA) is a complexing agent that can be used to synthesize contrast agents in oncology medicine.

HY-W046355

Fmoc-D-Dap(Boc)-OH	Radionuclide-Drug Conjugates (RDCs) Amino Acid Derivatives	Others
Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects .

HY-P3413A

H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH acetate	Peptides	Others
H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH (EM7) acetate is a linear mesenchymal stem cell (MSC) specific peptide. H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH acetate can be used to prepare Gd-DOTA-peptide complexes.

HY-P3413

H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH	Peptides	Inflammation/Immunology
H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH (EM7) is a linear mesenchymal stem cells (MSC)-specific peptide. H-Glu-Pro-Leu-Gln-Leu-Lys-Met-OH can be used to prepare Gd-DOTA-peptide complexes .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ ⁶⁸Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as ¹⁷⁷Lu and ²²⁵Ac. PSMA-D5 ([ ⁶⁸Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Cat. No.	Product Name	Target	Research Area

HY-P99239

Rosopatamab HUJ-591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

Cat. No.	Product Name		Classification

HY-140752

DOTA-PEG5-azide		PROTAC Synthesis Azide
DOTA-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-140314

DOTA-PEG5-C6-DBCO		DBCO PROTAC Synthesis
DOTA-PEG5-C6-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-PEG5-C6-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W782078

Butyne-DOTA		Alkynes
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W539916

Azido-mono-amide-DOTA		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-158065

*Azido-mono-amide-DOTA-tris(t-Bu ester)*		Azide
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

HY-140753

DOTA-(t-butyl)3-PEG5-azide		PROTAC Synthesis Azide
DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-(t-butyl)3-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-W451440

*Butyne-DOTA-tris(t-butyl ester)*		Alkynes
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: